C19orf35 Activators
C19orf35 engage diverse biochemical pathways to modulate its activity. Forskolin is a potent activator of adenylate cyclase, the enzyme responsible for converting ATP to the secondary messenger cyclic AMP (cAMP). This increase in cAMP levels directly leads to the activation of protein kinase A (PKA), which then can phosphorylate a range of substrates, including C19orf35, if it possesses the requisite phosphorylation sites. Similarly, IBMX functions by inhibiting phosphodiesterases, which are responsible for cAMP breakdown. By preventing the degradation of cAMP, IBMX indirectly maintains PKA in an active state, thus fostering a conducive environment for the phosphorylation of proteins like C19orf35. Prostaglandin E2 (PGE2), through its own receptors, and epinephrine, by binding to beta-adrenergic receptors, both initiate signaling cascades that culminate in elevated cAMP levels and subsequent PKA activation, creating the opportunity for C19orf35 activation via phosphorylation.
Other chemicals influence cAMP levels through targeted inhibition of specific phosphodiesterase isoforms. Rolipram and anagrelide selectively inhibit phosphodiesterase 4 and 3, respectively, resulting in increased cAMP within the cell and thereby sustaining PKA activity. Cilostamide, similar to anagrelide, focuses its action on PDE3, leading to the same outcome of enhanced PKA activity and possible C19orf35 phosphorylation. Dopamine and histamine, each interacting with their selective G-protein-coupled receptors, can also elevate cAMP in certain cellular contexts, which in turn activates PKA. Terbutaline, a beta2-adrenergic agonist, increases intracellular cAMP, thereby activating PKA. Lastly, zaprinast inhibits PDE5, which primarily breaks down cGMP, but its action also results in elevated cAMP levels, providing another route by which PKA can be activated and thus possibly lead to the phosphorylation of C19orf35.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, enzymes that break down cAMP. By preventing cAMP degradation, IBMX can indirectly sustain the activity of PKA, which may then phosphorylate and activate C19orf35. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 interacts with its G-protein-coupled receptors, which can lead to an increase in intracellular cAMP. This rise in cAMP can activate PKA, potentially leading to the phosphorylation and activation of C19orf35. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to beta-adrenergic receptors, triggering a G-protein-coupled response that leads to the production of cAMP and subsequent activation of PKA, which could phosphorylate and activate C19orf35. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine that activates beta-adrenergic receptors, leading to increased cAMP and activation of PKA, which may then phosphorylate and activate C19orf35. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which hydrolyzes cAMP. By inhibiting PDE4, rolipram increases cAMP levels, which can activate PKA that may phosphorylate and activate C19orf35. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase III (PDE3), leading to increased cAMP levels. The accumulation of cAMP can activate PKA, which in turn may phosphorylate and activate C19orf35. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective PDE3 inhibitor, which by increasing cAMP levels, can enhance PKA activity, potentially leading to the phosphorylation and activation of C19orf35. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can interact with its G-protein-coupled receptors, potentially increasing cAMP in certain cell types, which could lead to PKA-mediated phosphorylation and activation of C19orf35. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, through its H2 receptors, can lead to the activation of adenylate cyclase and an increase in cAMP, which in turn activates PKA, leading to the potential phosphorylation and activation of C19orf35. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline is a beta2-adrenergic agonist that increases intracellular cAMP, activating PKA, which could then phosphorylate and activate C19orf35. | ||||||